Drug intelligence / Profile preview

scopolamine

Development stage
Approved
Lead developer
GSK
Modality
Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration
Transdermal, Oral
01

Overview

Scopolamine is a tropane alkaloid and anticholinergic (antimuscarinic) agent derived from plants of the nightshade family. It acts primarily as a competitive antagonist at muscarinic acetylcholine receptors, inhibiting parasympathetic nerve impulses. Scopolamine is used mainly to prevent nausea and vomiting associated with motion sickness and postoperative recovery from anesthesia or opioid analgesia. It can also be used for gastrointestinal spasms, irritable bowel syndrome, preoperative reduction of respiratory secretions, and other indications such as clozapine-induced drooling or bowel colic. The most common formulation is a transdermal patch applied behind the ear that delivers medication over three days[1][3][4][5][10]. Side effects include dry mouth, blurred vision, drowsiness, confusion, tachycardia or bradycardia, urinary retention, constipation, hallucinations (especially at high doses), and withdrawal symptoms if discontinued after prolonged use[1][4][5]. Scopolamine is listed by the World Health Organization as an essential medicine due to its effectiveness and low cost[9].

Brand names
Transderm ScopTransderm-VMaldemar
Other names
scopolamine hydrobromidehyoscine hydrobromide
02

Targets

mAChR (Muscarinic acetylcholine receptors)

Beyond the preview

Go deeper on scopolamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on scopolamine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call